Abstract
Introduction: Invasive diagnostic techniques contribute to a late diagnosis and hence poor prognosis in patients with malignant pleural mesothelioma (MPM). Blood biomarkers, in particular low abundant tissue leakage proteins released after cell death or damage, seem promising as less invasive alternatives.
Aims: Validate our protocol to enrich plasma for tissue leakage proteins and identify new diagnostic biomarkers to discriminate MPM patients from healthy controls (HC).
Methods: Plasma samples from 5 MPM patients and 5 HC were collected and processed using a proprietary and currently confidential method to enrich for tissue leakage proteins. All samples were analysed by liquid chromatography-tandem mass spectrometry. Only protein groups with at least three valid measurements were considered for further statistical analysis.
Results: From a total of 508 identified unique proteins, 20 proteins had a significantly different expression pattern between the MPM and HC group (figure 1a). After removal of contaminants commonly found in plasma, 15 proteins remained significant (figure 1b). In future research these proteins will further be explored as diagnostic MPM biomarkers.
Conclusion: We were able to differentiate MPM patients from HC based on their plasma proteome enriched for tissue leakage proteins, which are less explored and therefore hold a lot of potential as MPM biomarkers.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1517.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021